A randomized controlled trial comparing capecitabine 5-days-on/2-days-off regimen with conventional regimen in stage II and III colorectal cancer.

ABSTRACT: Interventions: Capecitabine 5-days on/ 2-days off schedule Capecitabine conventional schedule Primary outcome(s): feasibility Study Design: Parallel Randomized

DISEASE(S): Stageii(high Risk) And Stageiii Resectable Colorectal Cancer

PROVIDER: 2647986 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR